RecruitingNCT05909761
Rare condition
Neuromyelitis optica spectrum disorder
44
studies recruiting now
as of 7 Sept 2026
187
studies registered in total
as of 7 Sept 2026
9
countries with a recruiting site
as of 7 Sept 2026
13 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
RecruitingPhase 3NCT05199688
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
RecruitingNCT06502015
Biomarkers in Autoimmune Disease of Nervous System
RecruitingPhase 1NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 44 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Neuromyelitis optica spectrum disorder study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Neuromyelitis optica spectrum disorder
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
3 approved treatments and 25 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Inebilizumab (Uplizna)Approved: Eculizumab (Bekemv)Approved: Satralizumab (Enspryng)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 3Bq 788
Phase 3Divozilimab
Phase 3Azathioprine (Azamune)
Phase 3Ravulizumab (Ultomiris)
Phase 2/3Daratumumab (Daratumumab component of darzalex faspro)
Phase 2/3Filgrastim (Accofil)
Phase 2/3Cyclophosphamide (Cyclophosphamide)
+ 17 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).